When Terry Pirovolakis learned his son had an ultra-rare neurodegenerative disease, SPG50, he refused to accept “no options.” What started as a desperate search for hope became Elpida Therapeutics, a nonprofit driving gene therapy innovation for multiple rare diseases. In this episode, Terry shares the remarkable journey from diagnosis to clinical trials, the power of partnerships, and why urgency matters when every day counts.
Podden och tillhörande omslagsbild på den här sidan tillhör
Charles River. Innehållet i podden är skapat av Charles River och inte av,
eller tillsammans med, Poddtoppen.
